Keppra and Localised oedema - a phase IV clinical study of FDA data
Summary:
Localised oedema is reported as a side effect among people who take Keppra (levetiracetam), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Neurontin, and have Nausea.
The phase IV clinical study analyzes which people have Localised oedema when taking Keppra. It is created by eHealthMe based on reports of 70,297 people who have side effects when taking Keppra from the FDA, and is updated regularly.
What is Keppra?
Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.
What is Localised oedema?
Localised oedema (fluid retention in a particular part of the body) is found to be associated with 552 drugs and 707 conditions by eHealthMe. Check the latest studies of Localised oedema.
70,297 people reported to have side effects when taking Keppra.
Among them, 21 people (0.03%) have Localised oedema.

Among these 21 people:
How long have people been on Keppra when they have Localised oedema? *
- < 1 month: 75 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 25 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Localised oedema when taking Keppra? *
- female: 73.68 %
- male: 26.32 %
What is the age of people who have Localised oedema when taking Keppra? *
- 0-1: 0.0 %
- 2-9: 5.88 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 23.53 %
- 40-49: 23.53 %
- 50-59: 11.76 %
- 60+: 35.29 %
What are other drugs people take besides Keppra? *
- Neurontin: 6 people, 28.57%
- Lasix: 5 people, 23.81%
- Tegretol: 4 people, 19.05%
- Protonix: 3 people, 14.29%
- Lyrica: 3 people, 14.29%
- Aldactone: 3 people, 14.29%
- Zofran: 3 people, 14.29%
- Copaxone: 3 people, 14.29%
- Avonex: 3 people, 14.29%
- Rebif: 3 people, 14.29%
What are other side effects people have besides Localised oedema? *
- Oedema Peripheral (superficial swelling): 8 people, 38.10%
- Speech Impairment (Adult) (inability to speak (adult)): 6 people, 28.57%
- Fatigue (feeling of tiredness): 6 people, 28.57%
- Dyspnea (difficult or laboured breathing): 5 people, 23.81%
- Grand Mal Convulsion (a type of generalized seizure that affects the entire brain): 5 people, 23.81%
- Mental Impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition): 5 people, 23.81%
- Joint Pain: 4 people, 19.05%
- Back Pain: 4 people, 19.05%
- Memory Loss: 4 people, 19.05%
- Dizziness: 4 people, 19.05%
What are the existing conditions these people have? *
- Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 14.29%
- Trigeminal Neuralgia (a painful condition of the nerve responsible for most facial sensation): 3 people, 14.29%
- Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 3 people, 14.29%
- Nausea (feeling of having an urge to vomit): 3 people, 14.29%
- Osteoporosis (bones weak and more likely to break): 2 people, 9.52%
- Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 9.52%
- Insomnia (sleeplessness): 2 people, 9.52%
- Pulmonary Hypertension (increase in blood pressure in the lung artery): 2 people, 9.52%
- Pain: 2 people, 9.52%
- Hypocalcaemia (levels of calcium in blood serum are abnormally low): 1 person, 4.76%
* Approximation only. Some reports may have incomplete information.
Do you take Keppra and have Localised oedema?
- Check whether Localised oedema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Keppra:
- Keppra (73,504 reports)
Localised oedema treatments and more:
- Localised oedema (5,668 reports)
How severe was Localised oedema and when was it recovered:
Expand to all the drugs that have ingredients of levetiracetam:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Keppra:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Localised oedema:
- Localised oedema (552 drugs)
Browse all the conditions that are associated with Localised oedema:
- Localised oedema (707 conditions)
Related publications that referenced our studies
- Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
- Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
- Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
- Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
- Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
- Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on levetiracetam (the active ingredients of Keppra) and Keppra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Darzalex cause High Blood Pressure? - 7 seconds ago
- Could Amitriptyline Hydrochloride cause Infusion Site Haemorrhage? - 10 seconds ago
- Could Carbidopa cause Headache? - 12 seconds ago
- Could Cleocin cause Exposed Bone In Jaw? - 19 seconds ago
- Cozaar vs. Doxazosin Mesylate, side effect and effectiveness comparison - 26 seconds ago
- Could Tessalon cause Nail Disorder? - 27 seconds ago
- Could Oxaliplatin cause Movement - Uncontrolled Or Slow? - 30 seconds ago
- Drug interactions of Ambien and Etoposide - 37 seconds ago
- Could Flomax cause Optic Neuritis? - 48 seconds ago
- Could Otezla cause Colon Cancer? - 48 seconds ago